cisplatin-teva concentrat pentru solutie perfuzabila 0,5 mg/ml
teva pharmaceutical industries ltd - cisplatinum - concentrat pentru solutie perfuzabila - 0,5 mg/ml
cisplatin-teva concentrat pentru solutie perfuzabila 0,5 mg/ml
teva pharmaceutical industries ltd - cisplatinum - concentrat pentru solutie perfuzabila - 0,5 mg/ml
cisplatin-teva concentrat pentru solutie perfuzabila 0,5 mg/ml
teva pharmaceutical industries ltd - cisplatinum - concentrat pentru solutie perfuzabila - 0,5 mg/ml
cisplatin-teva concentrat pentru solutie perfuzabila 1 mg/ml
teva pharmaceutical industries ltd - cisplatinum - concentrat pentru solutie perfuzabila - 1 mg/ml
carbidopa si levodopa-teva comprimate 250 mg + 25 mg
teva pharmaceutical industries ltd - levodopum + carbidopum - comprimate - 250 mg + 25 mg
carboplatin-teva concentrat pentru solutie perfuzabila 10 mg/ml
teva pharmaceutical industries ltd - carboplatinum - concentrat pentru solutie perfuzabila - 10 mg/ml
carboplatin-teva concentrat pentru solutie perfuzabila 10 mg/ml
teva pharmaceutical industries ltd - carboplatinum - concentrat pentru solutie perfuzabila - 10 mg/ml
carboplatin-teva concentrat pentru solutie perfuzabila 10 mg/ml
teva pharmaceutical industries ltd - carboplatinum - concentrat pentru solutie perfuzabila - 10 mg/ml
carboplatin-teva concentrat pentru solutie perfuzabila 10 mg/ml
teva pharmaceutical industries ltd - carboplatinum - concentrat pentru solutie perfuzabila - 10 mg/ml
clopidogrel teva
teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - tablets - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid